Company profile: Cantabio Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of preclinical biotechnology drug discovery research and therapeutic development focused on neurodegenerative and metabolic diseases, developing small-molecule DJ-1 protein-targeting therapeutics for Parkinson’s and other conditions and Tau protein-targeting therapeutics for Alzheimer’s and related tauopathies, integrating biophysics and novel technologies.
Products and services
- DJ-1 Protein Targeting Therapeutics: Develops preclinical-stage small-molecule drugs targeting DJ-1 protein for Parkinson’s disease and other conditions, creating DJ-1-focused therapeutic candidates
- Drug Discovery Research: Delivers biophysics-integrated discovery efforts that combine therapeutic focus and novel technologies to identify drug candidates for neurodegenerative and metabolic diseases
- Tau Protein Targeting Therapeutics: Architects protein-targeted therapeutics aimed at Tau protein for Alzheimer’s disease and related tauopathies, creating Tau-focused therapeutic candidates
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cantabio Pharmaceuticals
ArmaGen
HQ: United States
Website
- Description: Provider of therapies and siRNA delivery technologies that penetrate the blood-brain barrier to treat neurological complications of diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArmaGen company profile →
Cala Health
HQ: United States
Website
- Description: Provider of bioelectronic wearable neuromodulation devices for chronic diseases, including the Cala kIQ System that reduces hand tremors in essential tremor and Parkinson's disease via TAPS therapy, along with patient support, training, and reimbursement assistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cala Health company profile →
Amylyx Pharmaceuticals
HQ: United States
Website
- Description: Provider of solutions for Alzheimer’s and other brain diseases, offering ALS treatments such as RELYVRIO (U.S.)/ALBRIOZA (Canada) and AMX0035, a combination of sodium phenylbutyrate and taurursodiol studied for ALS and other neurodegenerative diseases, plus a patient support program with assistance and a free drug program for eligible patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amylyx Pharmaceuticals company profile →
NextWave Pharma
HQ: United States
Website
- Description: Provider of pharmaceutical products developed and commercialized using proprietary drug delivery technology; based in Cupertino, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NextWave Pharma company profile →
Helicon Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics to treat disorders of cognition, developed through understanding the genetic basis of long-term memory formation; originating from the neuroscience program at Cold Spring Harbor Laboratory.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helicon Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cantabio Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cantabio Pharmaceuticals
2.2 - Growth funds investing in similar companies to Cantabio Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cantabio Pharmaceuticals
4.2 - Public trading comparable groups for Cantabio Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →